Insilico Medicine discovers novel preclinical candidate to address idiopathic pulmonary fibrosis

By | February 25, 2021
Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence (“AI”) and drug discovery — linking together generative chemistry and biology for the first time — to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis (“IPF”) and be validated with multiple human cell and animal model experiments.